Is There a Role of Targeted Agents in the Management of Adrenocortical Cancers?

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Marker</td><td align="left">Inhibitors in clinical trials </td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">IGF 1 and 2<br/>IGF-1 receptor</td><td align="left">IMC-A12 (Cixutumumab)<br/>OSI-906</td></tr><tr><td align="left" colspan="2"><hr/></td></tr><tr><td align="left">Vascular endothelial growth factor (VEGF)</td><td align="left">Sorafenib<br/>Axitinib<br/>Bevacizumab </td></tr><tr><td align="left" colspan="2"><hr/></td></tr><tr><td align="left">mTOR (mammalian target of rapamycin)</td><td align="left">Temsirolimus</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

The cell markers and inhibitors in clinical trials.

Case Reports in Endocrinology

tab2

Table 2

Table 2: Is There a Role of Targeted Agents in the Management of Adrenocortical Cancers? 